Related Experiment Videos
Do irbesartan and amlodipine reduce cardiovascular events in diabetic patients?
1Family Practice Residency Program, Eastern Maine Medical Center, Bangor, USA. pmillard@emh.org
The Journal of Family Practice
|August 6, 2003
Insights
Neither irbesartan nor amlodipine reduced overall cardiovascular events in patients with diabetes and nephropathy. However, irbesartan lowered heart failure rates, while amlodipine reduced acute myocardial infarction incidence.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Investigated the impact of adding irbesartan (angiotensin receptor blocker) or amlodipine (calcium channel blocker) to antihypertensive regimens.
- Focused on patients with coexisting diabetes and nephropathy, a high-risk population for cardiovascular complications.
Discussion:
- Neither drug demonstrated a significant reduction in the overall incidence of major cardiovascular events.
- Irbesartan showed a specific benefit in reducing heart failure events.
- Amlodipine demonstrated a specific benefit in reducing acute myocardial infarction events.
Key Insights:
- Individual cardiovascular event types may be differentially affected by specific antihypertensive agents in diabetic nephropathy.
- Angiotensin receptor blockers and calcium channel blockers may offer distinct protective profiles beyond overall cardiovascular risk reduction.
- Treatment decisions may need to consider specific patient risk factors and potential drug-specific benefits.
Outlook:
- Further research is warranted to explore the mechanisms behind these differential effects.
- Personalized treatment strategies may emerge based on individual patient profiles and drug-specific outcomes.
- Optimizing antihypertensive therapy in diabetic nephropathy requires a nuanced approach considering various cardiovascular endpoints.
Abstract:
When added to antihypertensive treatment in patients with diabetes and nephropathy, neither the angiotensin receptor blocker (ARB) irbesartan nor the calcium channel blocker amlodipine reduced the overall occurrence of cardiovascular events. However, irbesartan decreased the rate of heart failure and amlodipine reduced the rate of acute myocardial infarction.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...